Specific activation of 2′-5′ oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: A potential for developing hepatitis C virus targeting gene therapy

World Journal of Gastroenterology

Volumn 15, Issue 25, 2009, Pages 3178-3182

  Wang, Ying ^a   Mao, Shan Shan ^b   He, Qiong Qiong ^a   Zi, Yuan ^a   Wen, Ji Fang ^a   Feng, De Yun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Core; 2 5 oligoadenylate synthetase; Gene promoter; Gene therapy; Hepatitis C virus

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ANTIBIOTIC G 418; CORE PROTEIN; PLASMID DNA;

ARTICLE; CONTROLLED STUDY; EMBRYO; GENE ACTIVATION; GENE AMPLIFICATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 67651246923     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3178     Document Type: Article

References (18)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S
2. Gonzalez-Aseguinolaza G, Crettaz J, Ochoa L, Otano I, Aldabe R, Paneda A. Gene therapy for viral hepatitis. Expert Opin Biol Ther 2006; 6: 1263-1278
3. Ji J, Glaser A, Wernli M, Berke JM, Moradpour D, Erb P. Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. J Gen Virol 2008; 89: 2761-2766
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362
5. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997; 25: 1527-1538
6. Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37: 209-220
7. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999; 258: 100-107
8. Shrivastava A, Manna SK, Ray R, Aggarwal BB. Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J Virol 1998; 72: 9722-9728
9. Kato N, Yoshida H, Ono-Nita SK, Kato J, Goto T, Otsuka M, Lan K, Matsushima K, Shiratori Y, Omata M. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000; 32: 405-412
10. Bergqvist A, Rice CM. Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J Virol 2001; 75: 772-781
11. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272: 10983-10986
12. Lee MN, Jung EY, Kwun HJ, Jun HK, Yu DY, Choi YH, Jang KL. Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway. J Gen Virol 2002; 83: 2145-2151
13. Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M, Shimotohno K, Kato N. Activation of the interferon-inducible 2′-5′-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 2000; 74: 8744-8750
14. Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 2001; 288: 379-390
15. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 2005; 191: 93-99
16. Weber F. Interaction of hepatitis C virus with the type I interferon system. World J Gastroenterol 2007; 13: 4818-4823
17. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001; 38: 177-192
18. Robson T, Hirst DG. Transcriptional Targeting in Cancer Gene Therapy. J Biomed Biotechnol 2003; 2003: 110-137